Herbec, Aleksandra http://orcid.org/0000-0002-3339-7214
Brown, Jamie
Shahab, Lion
West, Robert
Raupach, Tobias
Funding for this research was provided by:
Pfizer
British Heart Foundation, BHF (FS/13/59/30649)
Cancer Research UK (C1417/A22962)
Article History
Received: 25 February 2019
Accepted: 9 August 2019
First Online: 2 September 2019
Ethics approval and consent to participate
: The study received ethical approval from the University College London Research Ethics Committee (ID: 5398/001). All participants provided informed consent before participating.
: Not applicable.
: AH led the development of the NRT2Quit app and the NRT2Quit trial as part of her PhD funded by British Heart Foundation 4-year PhD at University College London, has conducted administrative tasks for the NRT2Quit trial in a paid capacity from GRAND, and has received unrestricted funds as part of a project <i>Global Bridges at Mayo Clinic and Pfizer</i> Independent <i>Grants</i> for Learning and Change Request for Proposals: <i>EUROPEAN PROGRAM</i>. LS has received honoraria for talks, an unrestricted research grant and travel expenses to attend meetings and workshops from Pfizer and Johnson & Johnson and has acted as a paid reviewer for grant-awarding bodies and as a paid consultant for healthcare companies. Other research has been funded by the government, a community-interested company (National Centre for Smoking Cessation) and charitable sources. JB received unrestricted research grants to study smoking cessation from Pfizer who manufacture smoking cessation medications. RW undertakes research and consultancy and receives fees for speaking from companies that develop and manufacture smoking cessation medications (Pfizer, Johnson & Johnson, GlaxoSmithKline). JB and RW are both unpaid members of the scientific steering group of the Smoke Free mobile application. TR has received honoraria from Pfizer, Novartis, GlaxoSmithKline, AstraZeneca and Roche as a speaker in activities related to continuing medical education. He has also received financial support for investigator-initiated trials from Pfizer and Johnson & Johnson. The views presented are not necessarily the views of the funders.